Osavampator
Chemical compound
Osavampator (developmental code names TAK-653 and NBI-1065845) is an experimental drug being investigated as a treatment for treatment-resistant depression. It is being developed by Neurocrine Biosciences and Takeda Pharmaceuticals (Millennium Pharmaceuticals, Inc.).
Nº Q116977443 ★
Common · Knowledge
Osavampator
Chemical compound
Osavampator (developmental code names TAK-653 and NBI-1065845) is an experimental drug being investigated as a treatment for treatment-resistant depression. It is being developed by Neurocrine Biosciences and Takeda Pharmaceuticals (Millennium Pharmaceuticals, Inc.).
From Wikipedia
Osavampator (developmental code names TAK-653 and NBI-1065845) is an experimental drug being investigated as a treatment for treatment-resistant depression. It is being developed by Neurocrine Biosciences and Takeda Pharmaceuticals (Millennium Pharmaceuticals, Inc.). Takeda Pharmaceuticals discovered the molecule originally, and holds exclusive right to market the drug in Japan, while Neurocrine Biosciences holds the right to market it to the rest of the world.
Text: Wikipédia, CC BY-SA 4.0. · Image: User:Innerstream (Public domain) ·
Related cards
-
Coluracetam
Chemical compound
Nº Q3683872 ★
Not listed
-
Ipidacrine
Chemical compound
Nº Q15409425 ★
Not listed
-
Seltorexant
Chemical compound
Nº Q27273944 ★
Not listed
-
Clomipramine
Chemical compound
Nº Q58713 ★★★
Not listed
-
Tiagabine
Chemical compound
Nº Q907219 ★
Not listed
-
Serotonin–norepinephrine reuptake inhibitor
Class of antidepressant drugs used in the treatment of major depressive disorder
Nº Q2273909 ★★★
Not listed